Drug Trial Radar · NCT04099966
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Apr 1, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Mitchell CairoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 day, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Conditions
- Acute Leukemia
- Severe Aplastic Anemia
- Non-hodgkin Lymphoma
- Hodgkin Lymphoma
- Kostmann
- Diamond Blackfan Anemia
- Amegakaryocytic Thrombocytopenia
- Sickle Cell Disease
- Beta-Thalassemia
Interventions
alpha beta depletionDrug
donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cellsTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New York Medical College
Valhalla, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.